European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

9th ESOU Meeting re-examines prostate cancer issues on screening, biopsies and imaging

Fri, 20 Apr 2012

The issue of prostate cancer screening remains a much-discussed topic but recent studies are proving that screening decreases prostate cancer mortality, according to J. Hugosson who lectured during the three-day 9th ESOU (EAU Section of Oncological Urology) Meeting which opened today in Hamburg, Germany.

“Screening decreases prostate cancer mortality, but whether organized screening is better than non organized (opportunistic) is not yet established,” said Hugosson. Hugosson also said that harms with PSA screening are considerable but how it affects individual patients vary.

“The efficacy of screening seems to vary considerably between different screening programmes,” he said and stressed that “it is not a question of “if” to screen but how and who should be screened.”

With around 700 participants the 9th ESOU Meeting discussed a wide range of issues and the latest developments in prostate, renal, bladder, penile and testis cancers.

“For this meeting we are examining in various lectures, debates and discussions the latest and key developments in uro-oncology,” said ESOU chairman Maurizio Brausi (IT) and meeting president Gerald Mickisch (DE). F. Klose (DE) gave the opening remarks and welcomed all participants as he emphasised the importance of multi-disciplinary collaboration.

The opening plenary session tackled prevention strategies in prostate cancer with B. Schmitz-Drager (DE) discussing prevention strategies and its relevance in clinical practice, while B. Djavan lectured on negative biopsies. K. Pummer provided an update on innovations on diagnostic imaging. The first session on prostate cancer ended with a debate by M. Wirth (DE) and A. Mendoza-Valdes (MX), with the former defending the EAU guidelines on intermittent hormonal therapy as a standard for PCa and the latter re-examining its benefits.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer